Targets and strategies for vaccine development against dengue viruses - 13/11/21
pages | 13 |
Iconographies | 5 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Dengue virus (DENV) is a global health threat causing about half of the worldwide population to be at risk of infection, especially the people living in tropical and subtropical area. Although the dengue disease caused by dengue virus (DENV) is asymptomatic and self-limiting in most people with first infection, increased severe dengue symptoms may be observed in people with heterotypic secondary DENV infection. Since there is a lack of specific antiviral medication, the development of dengue vaccines is critical in the prevention and control this disease. Several targets and strategies in the development of dengue vaccine have been demonstrated. Currently, Dengvaxia, a live-attenuated chimeric yellow-fever/tetravalent dengue vaccine (CYD-TDV) developed by Sanofi Pasteur, has been licensed and approved for clinical use in some countries. However, this vaccine has demonstrated low efficacy in children and dengue-naïve individuals and also increases the risk of severe dengue in young vaccinated recipients. Accordingly, many novel strategies for the dengue vaccine are under investigation and development. Here, we conducted a systemic literature review according to PRISMA guidelines to give a concise overview of various aspects of the vaccine development process against DENVs, mainly targeting five potential strategies including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral-vector vaccine, and DNA vaccine. This study offers the comprehensive view of updated information and current progression of immunogen selection as well as strategies of vaccine development against DENVs.
Le texte complet de cet article est disponible en PDF.Highlights |
• | Dengue Virus NS1 and E proteins are the main targets for vaccine candidates. |
• | Pathogenesis of DHF and DSS are still not fully understood. |
• | Currently five types of dengue vaccines are under investigation and development. |
• | CYD-TDV is the first licensed dengue vaccine live attenuated vaccine. |
Keywords : Dengue virus, Dengue vaccine, Live-attenuated virus, Inactivated virus, DNA vaccine, Subunit vaccine, Viral-vector vaccine, Review
Plan
Vol 144
Article 112304- décembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?